Introduction of ZEISS Imaging Systems for Super-Resolution

Webinar recording about the ZEISS Lattice SIM technology.

Trumps nya FDA-chef varnar för "massiv övermedicinering"

Donald Trump har nominerat kirurgen och författaren Marty Makary till ny chef för den amerikanska läkemedelsmyndigheten FDA, som enligt den tillträdande preside...

19 medicines in Sweden are under investigation in a major EMA inquiry

unless new evidence can be provided that they are up to standard.

Trump aviserar ny prispress – läkemedelsjättar faller

USA:s president Donald Trump har återigen riktat fokus mot landets läkemedelspriser. Han presenterar nu två separata initiativ för att pressa priserna på diabet...

Medicon Valley Alliance

ZEISS Quality Innovations at CONTROL

May 6-9, 2025 in Stuttgart.

Individual DNA passport could result in fewer drug side effects

You may be required to show a DNA passport when you pick up medicines at the pharmacy in the future. According to a new study, patients might suffer 30% fewer s...

Tre chefsrockader i CTR-koncernen

Forskningskoncernen Center for Translational Research (CTR) genomför flera skiften på ledande positioner. Flera av bolagen inom gruppen får nu nya chefer.

Explore 3D Testing of Deformation and Motions

Powerful measurement capabilities with the new ZEISS ARAMIS 1.

Just four weeks to a concept for an emergency ventilator

The lockdown in spring 2020 meant that the majority of Festo employees had to join the ranks of those working from home. Yet within the space of just four weeks...

Ingrid Lönnstedt: What does the p-value mean?

The smaller the better, and preferably smaller than 0.05. A p-value smaller than 5% means that the treatment effect is statistically significant at 5% significa...

Acquisition of consulting company Key2Compliance

The Swedish company Key2Compliance, offering services in fields such as pharma and Medtech, has been acquired by German GBA Group.

“Unfortunately, we are not strong when it comes to conducting clinical trials”

The number of company-initiated clinical trials conducted in Sweden has been declining in recent years. In mid-March, a government inquiry was presented that ai...

Tirzepatide approved for obesity by the FDA – to be branded as Zepbound

Diabetes drug tirzepatide has now also been approved in the US for treating obesity.

Heidi Stensmyren is eager for new challenges in the biotech industry

Heidi Stensmyren has served as President of the Swedish Medical Association, held a managerial position at Karolinska University Hospital and is now Medical Dir...

A billion-dollar acquisition makes Novo Nordisk even bigger in obesity

Danish pharmaceutical giant Novo Nordisk acquires Montreal-based Inversago Pharma, which develops treatments for obesity and diabetes.

ZEISS Insights: Measurement of bone plates and screws

Get free access to technical paper.

Lucy Robertshaw: Artificial intelligence – is this really going to transform a patient’s life?

In a column Lucy Robertshaw reflects on how AI and new regulations will affect healthcare, innovation and the lives of future patients.

On the hunt for high throughput diagnostics

Global diagnostics companies and laboratories are in a race against time to adapt testing capacity to current demand. Due to the global COVID 19 pandemic, the d...

Novo Nordisk to invest billions in Danish manufacturing facilities

Danish pharmaceutical giant Novo Nordisk is investing DKK 42 billion, equivalent to around SEK 65 billion/EUR 5.6 billion, in its manufacturing facilities in Ka...

Small robots to deliver pharmaceuticals to the body

Robots that can operate inside the body and a platform that combines ultrasound with AI. These are a couple of the technologies that have qualified for a list t...

Setback for Moderna in patent dispute with mRNA competitors

Moderna has suffered a setback in a patent battle against their worst competitors in covid vaccines, Biontech and its partner Pfizer.

Marie Gårdmark: ”The situation is not satisfactory”

”The legislative tool-box is limited, but carrots in the form of longer exclusivity has already proven successful, this has for example increased registration of new products in rare diseases. But will it also work to increase access for all EU patients...

ZEN core now available for all ZEISS scanning electron microscopes

Introducing intuitive, streamlined SEM control over imaging, analytics, and multi-modal workflows.